2019

1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

   The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628